{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cabergoline+1+MG",
    "query": {
      "intervention": "Cabergoline 1 MG"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 6,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-14T06:39:56.012Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00033111",
      "title": "A Study of Cabergoline for the Treatment of Cocaine Dependence - 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cocaine-Related Disorders",
        "Substance-Related Disorders"
      ],
      "interventions": [
        {
          "name": "Cabergoline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Drug Abuse (NIDA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 140,
      "start_date": "2001-06",
      "completion_date": "2004-04",
      "has_results": false,
      "last_update_posted_date": "2017-01-12",
      "last_synced_at": "2026-09-14T06:39:56.012Z",
      "location_count": 2,
      "location_summary": "Torrance, California • Charleston, South Carolina",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00033111"
    },
    {
      "nct_id": "NCT01395602",
      "title": "Effect of Cabergoline on Weight and Glucose Tolerance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Body Weight",
        "Impaired Glucose Tolerance in Obese"
      ],
      "interventions": [
        {
          "name": "Cabergoline",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2002-04",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2015-10-14",
      "last_synced_at": "2026-09-14T06:39:56.012Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01395602"
    },
    {
      "nct_id": "NCT00605683",
      "title": "MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Idiopathic Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Safinamide (as add-on therapy)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Newron Pharmaceuticals SPA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 679,
      "start_date": "2007-11",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2013-10-29",
      "last_synced_at": "2026-09-14T06:39:56.012Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Oxnard, California + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Sunnyvale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00605683"
    },
    {
      "nct_id": "NCT07492160",
      "title": "Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pregnancy",
        "Abortion"
      ],
      "interventions": [
        {
          "name": "Cabergoline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Maimonides Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 348,
      "start_date": "2026-03-16",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-25",
      "last_synced_at": "2026-09-14T06:39:56.012Z",
      "location_count": 1,
      "location_summary": "Brooklyn, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07492160"
    },
    {
      "nct_id": "NCT04701333",
      "title": "Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lactation Suppressed"
      ],
      "interventions": [
        {
          "name": "Cabergoline 1 MG",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 73,
      "start_date": "2021-04-01",
      "completion_date": "2023-03-01",
      "has_results": true,
      "last_update_posted_date": "2024-02-13",
      "last_synced_at": "2026-09-14T06:39:56.012Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04701333"
    },
    {
      "nct_id": "NCT06029673",
      "title": "Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lactation Suppressed"
      ],
      "interventions": [
        {
          "name": "Cabergoline 1 MG",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 69,
      "start_date": "2024-02-07",
      "completion_date": "2025-07-01",
      "has_results": true,
      "last_update_posted_date": "2025-10-03",
      "last_synced_at": "2026-09-14T06:39:56.012Z",
      "location_count": 2,
      "location_summary": "San Jose, California • Stanford, California",
      "locations": [
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06029673"
    }
  ]
}